Belite Bio, Inc
BLTE
$65.36
$0.360.55%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.64% | 63.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.55% | 59.53% | |||
| Operating Income | 36.55% | -59.53% | |||
| Income Before Tax | 36.06% | -60.58% | |||
| Income Tax Expenses | -200.00% | -66.67% | |||
| Earnings from Continuing Operations | 36.08% | -60.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.08% | -60.53% | |||
| EBIT | 36.55% | -59.53% | |||
| EBITDA | 36.77% | -59.66% | |||
| EPS Basic | 38.32% | -51.51% | |||
| Normalized Basic EPS | -- | -- | |||
| EPS Diluted | 38.32% | -51.51% | |||
| Normalized Diluted EPS | -- | -- | |||
| Average Basic Shares Outstanding | 3.66% | 5.94% | |||
| Average Diluted Shares Outstanding | 3.66% | 5.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
